After floating an initial range of $12 to $14 per share, AcelRx Pharmaceuticals Inc. priced its initial public offering (IPO) at $5. The move is consistent with IPOs by other companies in the industry, which are finding that more shares at a lower price is the way to attract buyers in a post-2008 economy.